Scientific Director Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Scientific Director


With 20 years of progressive experience in the biopharmaceutical industry in research, discovery and development to advance programs towards early clinical development, Dr. Zhang will lead current scientific programs, as well as future investments in the platform. shape and pipeline for autologous platform company iPSC.

“As Aspen grows, we are delighted to welcome Dr. Zhang,” said Damien mcdevitt, Ph.D., President and CEO of Aspen Neuroscience. “Xiaokui’s expertise, which combines a solid background in stem cell research with a solid background in the regenerative medicine industry, will be important for Aspen as we grow on the solid foundation built by our amazing and growing R&D team. “

“The next frontier in medicine lies at the intersection of autologous and personalized medicine for each patient,” said Dr. Zhang. “The team that built the Aspen platform have accomplished feats that would not have been possible even 10 years ago, including combining autologous stem cells and AI-based bioinformatics to develop personalized therapies for patients with unmet medical needs . I am honored and thrilled with this rare opportunity to lead the next stage of aspen scientific vision. ”

Dr. Zhang’s research on the functional characterizations of JAK-STAT signaling pathways and the differentiation of placental progenitor cells has resulted in numerous patents and publications in leading journals, including Science. She has also served as a mentor to junior professionals at the International Society for Cell and Gene Therapy (ISCT) and is the recipient of the Women in Science, Technology, Engineering and Mathematics (STEM) Award from the New Jersey Liberty Science Center.

Before joining Aspen. Dr. Zhang served as Executive Vice President and Scientific Director of Celularity Inc., overseeing the discovery, candidate development, preclinical, translational, process development and CMC activities to develop allogeneic cell therapy product candidates derived from the placenta for immuno-oncology and functional regeneration applications. Dr. Zhang has also held various positions of increasing scope and responsibility at Celgene Cellular Therapeutics, including Director of Discovery Research and Senior Director of Research and Development. Prior to Celgene, Dr. Zhang led a gene discovery team at Helicon Therapeutics and conducted target identification studies in cognitive impairment.

Dr. Zhang received her undergraduate degree in physiology from Nankeen University, Jiangsu, China and his doctorate in molecular cell biology from Rockefeller University, New York, New York, with additional post-doctoral training in functional genomics at Novartis Pharmaceuticals.

IN REGARDS TO TREMBLE NEUROSCIENCE
Based at San Diego, Aspen Neuroscience, Inc. is a privately held, developmental biotechnology company focused on personalized (autologous) cell therapies. The company is developing induced pluripotent stem cells (iPSCs) to treat diseases with high unmet medical need, starting with the replacement of autologous neurons for sporadic and genetic forms of Parkinson’s disease (PD) and extending to through the brain and affected organs.

A leading company in the iPSC platform, Aspen combines stem cell biology with the latest approaches in artificial intelligence and genomics to study patient-specific restorative treatments. The company has developed an advanced platform to create and characterize cellular drugs derived from pluripotents, which includes bioinformatics, in-house manufacturing and quality control. For more information and important updates, please visit http://www.aspenneuroscience.com.

SOURCE Aspen Neuroscience, Inc.


Comments are closed.